Hepatocellular carcinoma (HCC), the most common primary cancer of the liver, often develops in people with chronic liver disease caused by hepatitis B or C, alcohol-associated liver injury, or metabolic dysfunction. Detecting the disease at an early stage can expand treatment options, yet reliable blood-based markers remain limited. A study by Xie, Ye, Yu and colleagues, published in the British Journal of Cancer, examines aldo-keto reductase 1B10, or AKR1B10, as a potential serum marker for both diagnosing HCC and monitoring patients immediately after surgery.
AKR1B10 is an enzyme belonging to the aldo-keto reductase superfamily, a group of proteins involved in the reduction of aldehydes and ketones and in the regulation of cellular responses to oxidative stress. The enzyme has been associated with lipid metabolism, detoxification processes and the handling of reactive carbonyl compounds. In several cancers, including liver tumors, altered AKR1B10 expression has been linked to changes in cellular metabolism and tumor biology, making it a candidate biomarker for translating molecular changes inside a tumor into a measurable signal in the bloodstream.
The clinical appeal of a serum marker is straightforward: blood testing is less invasive and easier to repeat than tissue sampling or imaging. At present, alpha-fetoprotein, commonly known as AFP, is widely used in HCC assessment, but its sensitivity and specificity are not sufficient for every patient. Some tumors produce little or no AFP, while elevated levels can also occur in non-cancerous liver conditions. Researchers have therefore continued to search for complementary markers that can improve diagnostic confidence, particularly in people with cirrhosis or chronic hepatitis, where distinguishing malignant from non-malignant changes can be difficult.
The new study focuses on whether AKR1B10 can provide clinically useful information in serum. Measuring a protein or enzyme in blood requires more than demonstrating that it is present: researchers must determine whether its concentration differs meaningfully between patients with HCC and appropriate comparison groups. They must also assess how consistently the marker identifies disease, how frequently it produces false-positive results, and whether it adds information beyond established tests such as AFP, liver-function measurements and imaging examinations.
The investigators also examined AKR1B10 in the immediate postoperative setting, an area with particular importance for liver cancer care. Surgical removal of a tumor can produce a rapid change in the concentration of tumor-associated molecules circulating in the blood. If AKR1B10 levels fall after a complete resection, that pattern could support the interpretation that the main source of the marker has been removed. Conversely, persistently high or unexpectedly rising levels might indicate residual tumor tissue, early recurrence or biological information that warrants closer clinical evaluation.
Postoperative monitoring is challenging because surgery itself causes inflammation, tissue injury and temporary changes in liver function. These effects can influence blood-based measurements and complicate the interpretation of any single result. For that reason, a marker intended for immediate monitoring must be evaluated in relation to timing, baseline concentration and the patient’s clinical condition. Serial measurements may be more informative than one postoperative value, as trends can reveal whether a biomarker is moving in the direction expected after tumor removal.
AKR1B10 could be biologically relevant to HCC because malignant liver cells often undergo profound metabolic reprogramming. Tumor cells alter the way they process lipids, carbohydrates and reactive molecules in order to sustain rapid growth and survive under stress. An enzyme involved in carbonyl metabolism and oxidative-stress control may therefore reflect more than the presence of a mass; it may also mirror the biochemical state of the tumor. However, a plausible mechanism does not by itself establish clinical usefulness. The value of AKR1B10 must ultimately be determined by carefully measured diagnostic performance and by evidence that testing changes patient management.
The study’s findings are positioned within a broader effort to develop more precise, minimally invasive tools for HCC care. A useful biomarker could help clinicians identify patients who need additional imaging, support decisions about treatment, and provide an early indication of how the disease is responding after surgery. It could be particularly valuable when used alongside AFP rather than as a replacement, since combining markers that reflect different aspects of tumor biology can sometimes improve diagnostic accuracy. The practical impact would depend on assay standardization, reproducibility between laboratories and confirmation in larger, independent patient populations.
The researchers’ evaluation of AKR1B10 therefore addresses two linked clinical questions: whether the enzyme can help distinguish HCC from other liver conditions before treatment, and whether its serum concentration changes in a clinically interpretable way after tumor removal. If validated, AKR1B10 could become part of a broader surveillance strategy combining blood biomarkers, radiological imaging and clinical assessment. Such an approach would not eliminate the need for specialist evaluation, but it could offer a faster and more repeatable window into tumor status.
The work highlights the continuing shift in cancer diagnostics from single, imperfect indicators toward integrated molecular monitoring. For patients with HCC, the ultimate goal is not simply to discover a marker that is elevated in cancer, but to develop a test that improves decisions across the patient journey—from initial detection to postoperative surveillance and the recognition of possible recurrence. AKR1B10 now represents a candidate for that process. Its future clinical role will depend on further validation, particularly studies that compare it directly with AFP, test it across diverse liver-disease populations and determine whether AKR1B10-guided monitoring improves outcomes.
Subject of Research: Aldo-keto reductase 1B10 (AKR1B10) as a serum biomarker for hepatocellular carcinoma diagnosis and immediate postoperative monitoring.
Article Title: AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma.
Article References: Xie, M., Ye, X., Yu, Q. et al. AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03530-x
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41416-026-03530-x
Keywords: AKR1B10, hepatocellular carcinoma, liver cancer, serum biomarker, cancer diagnosis, postoperative monitoring, AFP, oncology, liver disease, biomarker research
Tags: AKR1B10 serum markerblood-based liver cancer diagnosticsearly detection of liver tumorshepatocellular carcinoma biomarkerslipid metabolism in liver cancerliver cancer diagnosismolecular biomarkers for HCCnon-invasive liver cancer detection methodsoxidative stress and liver tumor biologypostoperative liver cancer monitoringrole of AKR1B10 in cancertumor metabolic alterations in HCC
